Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

June 01, 2006 (Vol. 26, No. 11)

Biofirms Develop Novel Therapeutics for MS

Major Research Focus is on T Cells

  • Acorda Therapeutics (www.acorda.com) recently completed enrollment of its Phase III trial of Fampridine-SR in multiple sclerosis (MS). The study, which is based on a Special Protocol Assessment issued by the FDA, is evaluating the safety and efficacy of Fampridine-SR in improving walking ability in people with MS. Secondary outcomes ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.